Literature DB >> 27081094

How to avoid being eaten: a lymphoma's defense.

Nora Heisterkamp1.   

Abstract

In this issue of Blood, Lykken et al used an immunocompetent mouse model of B-cell lymphoma to discover an interesting new way in which these malignant cells can avoid being killed in the presence of anti-CD20 antibodies.

Entities:  

Mesh：

Year:  2016        PMID： 27081094      PMCID： PMC4832503          DOI： 10.1182/blood-2016-03-701680

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Galectins as therapeutic targets for hematological malignancies: a hopeful sweetness.

Authors:  Camilo Pena; Leonardo Mirandola; Jose A Figueroa; Nattamol Hosiriluck; Natallia Suvorava; Kayley Trotter; Adair Reidy; Rahman Rakhshanda; Drew Payne; Marjorie Jenkins; Fabio Grizzi; Lauren Littlefield; Maurizio Chiriva-Internati; Everardo Cobos
Journal:  Ann Transl Med       Date:  2014-09

2.  Taloside inhibitors of galectin-1 and galectin-3.

Authors:  Patrick M Collins; Christopher T Oberg; Hakon Leffler; Ulf J Nilsson; Helen Blanchard
Journal:  Chem Biol Drug Des       Date:  2012-01-11       Impact factor: 2.817

3.  A novel function for galectin-1 at the crossroad of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway.

Authors:  Paula Barrionuevo; Macarena Beigier-Bompadre; Juan M Ilarregui; Marta A Toscano; Germán A Bianco; Martín A Isturiz; Gabriel A Rabinovich
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

Review 4.  Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.

Authors:  Benjamin Bonavida
Journal:  Semin Oncol       Date:  2014-08-12       Impact factor: 4.929

Review 5.  The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target.

Authors:  A Neil Barclay; Timo K Van den Berg
Journal:  Annu Rev Immunol       Date:  2013-11-06       Impact factor: 28.527

Review 6.  Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer.

Authors:  Nuray Gül; Marjolein van Egmond
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

7.  Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms.

Authors:  Jacquelyn M Lykken; Mayuka Horikawa; Veronique Minard-Colin; Masahiro Kamata; Tomomitsu Miyagaki; Jonathan C Poe; Thomas F Tedder
Journal:  Blood       Date:  2016-02-17       Impact factor: 22.113

8.  Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.

Authors:  Ruud P M Dings; Michelle C Miller; Irina Nesmelova; Lucile Astorgues-Xerri; Nigam Kumar; Maria Serova; Xuimei Chen; Eric Raymond; Thomas R Hoye; Kevin H Mayo
Journal:  J Med Chem       Date:  2012-05-30       Impact factor: 7.446

9.  Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma.

Authors:  Diego O Croci; Mariana Salatino; Natalia Rubinstein; Juan P Cerliani; Lucas E Cavallin; Howard J Leung; Jing Ouyang; Juan M Ilarregui; Marta A Toscano; Carolina I Domaica; María C Croci; Margaret A Shipp; Enrique A Mesri; Adriana Albini; Gabriel A Rabinovich
Journal:  J Exp Med       Date:  2012-10-01       Impact factor: 14.307

Review 10.  Macrophages are critical effectors of antibody therapies for cancer.

Authors:  Kipp Weiskopf; Irving L Weissman
Journal:  MAbs       Date:  2015       Impact factor: 5.857
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.